Literature DB >> 33261700

Group transdiagnostic cognitive-behavior therapy for anxiety disorders: a pragmatic randomized clinical trial.

Pasquale Roberge1,2, Martin D Provencher3, Isabelle Gaboury1,2, Patrick Gosselin4, Helen-Maria Vasiliadis5, Annie Benoît1,2, Nathalie Carrier1,2, Martin M Antony6, Nils Chaillet7, Janie Houle8, Catherine Hudon1,2, Peter J Norton9.   

Abstract

BACKGROUND: Transdiagnostic group cognitive-behavioral therapy (tCBT) is a delivery model that could help overcome barriers to large-scale implementation of evidence-based psychotherapy for anxiety disorders. The aim of this study was to assess the effectiveness of combining group tCBT with treatment-as-usual (TAU), compared to TAU, for the treatment of anxiety disorders in community-based mental health care.
METHODS: In a multicenter single-blind, two-arm pragmatic superiority randomized trial, we recruited participants aged 18-65 who met DSM-5 criteria for principal diagnoses of generalized anxiety disorder, social anxiety disorder, panic disorder, or agoraphobia. Group tCBT consisted of 12 weekly 2 h sessions. There were no restrictions for TAU. The primary outcome measures were the Beck Anxiety Inventory (BAI) and clinician severity rating from the Anxiety and Related Disorders Interview Schedule for DSM-5 (ADIS-5) for the principal anxiety disorder at post-treatment, with intention-to-treat analysis.
RESULTS: A total of 231 participants were randomized to either tCBT + TAU (117) or TAU (114), with outcome data available for, respectively, 95 and 106. Results of the mixed-effects regression models showed superior improvement at post-treatment for participants in tCBT + TAU, compared to TAU, for BAI [p < 0.001; unadjusted post-treatment mean (s.d.): 13.20 (9.13) v. 20.85 (10.96), Cohen's d = 0.76] and ADIS-5 [p < 0.001; 3.27 (2.19) v. 4.93 (2.00), Cohen's d = 0.79].
CONCLUSIONS: Our findings suggest that the addition of group tCBT into usual care can reduce symptom severity in patients with anxiety disorders, and support tCBT dissemination in routine community-based care.

Entities:  

Keywords:  Anxiety disorders; community mental health services; group psychotherapy; randomized controlled trial; transdiagnostic cognitive-behaviour therapy

Year:  2020        PMID: 33261700     DOI: 10.1017/S0033291720004316

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  4 in total

1.  French adaptation and validation of the Panic Disorder Severity Scale-self-report.

Authors:  Pasquale Roberge; Patricia Marx; Jonathan Couture; Nathalie Carrier; Annie Benoît; Martin D Provencher; Martin M Antony; Peter J Norton
Journal:  BMC Psychiatry       Date:  2022-06-27       Impact factor: 4.144

Review 2.  Evidence-Based Pharmacotherapy of Generalised Anxiety Disorder: Focus on Agomelatine.

Authors:  Dan J Stein
Journal:  Adv Ther       Date:  2021-08-21       Impact factor: 3.845

3.  A pragmatic randomized controlled trial of a group self-management support program versus treatment-as-usual for anxiety disorders: study protocol.

Authors:  Pasquale Roberge; Janie Houle; Jean-Rémy Provost; Simon Coulombe; Annie Beaudin; Peter Bower; Félix Camirand Lemyre; Martin Drapeau; Marc-Simon Drouin; Catherine Hudon; Martin D Provencher; Helen-Maria Vasiliadis
Journal:  BMC Psychiatry       Date:  2022-02-21       Impact factor: 3.630

Review 4.  Strategies to improve access to cognitive behavioral therapies for anxiety disorders: A scoping review.

Authors:  Jean-Daniel Carrier; Frances Gallagher; Alain Vanasse; Pasquale Roberge
Journal:  PLoS One       Date:  2022-03-01       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.